PCSK9 and diabetes mellitus: Evidence gained from randomized controlled trials using PCSK9 inhibitors in secondary prevention suggests a similar efficacy on LDL-C reduction and clinical benefit in patients with diabetes mellitus compared to those without diabetes [7, 8].